Update to Member Cost Sharing for Treatment of COVID-19

Posted on 2021-09-01
Updated on 2021-09-01 09:00:00

Monoclonal Antibody Treatment Costs Continue to be Waived

In June, CareFirst BlueCross BlueShield announced effective September 1, 2021, we would no longer waive member costs (copay, coinsurance and deductible) related to the treatment of COVID-19. This change applies to all commercial members. 

Please note the following update to that communication: CareFirst will continue to waive member costs for monoclonal antibody treatments. Monoclonal antibody treatments are indicated for patients with mild to moderate disease at high risk to progress to severe COVID and for post exposure prophylaxis for those who are not fully vaccinated or immunocompromised and have been exposed to an infected individual.

Note: COVID-19 vaccination is not considered treatment and will remain at zero cost share for members. 

Providers are encouraged to check eligibility and benefits on CareFirst Direct or by calling the Provider Service number on the back of the member ID card. 

To stay up-to-date on COVID-19 policies and benefits updates, visit our Coronavirus Resource Center.